Medications for Addiction Treatment (MAT) in New Jersey
Medications for addiction treatment, often called MAT, are FDA-approved medicines used to treat opioid use disorder and alcohol use disorder, usually together with counseling and other support. You may also see MOUD (medications for opioid use disorder) or MAUD (medications for alcohol use disorder). Medication is not a separate level of care. It can be part of treatment at almost every level, from a primary care office to a residential program.
This guide explains the medications, where New Jersey residents can get them, how the State licenses opioid treatment programs, what NJ FamilyCare and private insurance require, and how to get free naloxone. It is general information, not medical advice. Only a prescriber who evaluates you can decide whether a medication is right for you and which one.
If you need help right now
- Overdose or emergency: call 911. New Jersey law protects people who call for help in good faith during an overdose from arrest and prosecution for certain drug possession offenses. If you have naloxone, use it.
- Crisis: call or text 988 (free, confidential, 24/7).
- ReachNJ, 1-844-732-2465: the State's free 24/7 addiction helpline, for help regardless of insurance or ability to pay.
- IME Addictions Access Center, 1-844-276-2777 (24/7): the State's contracted access center, which can do a phone assessment and help connect you to treatment, including medication.
Do not stop or change a prescribed medication on your own. Stopping opioids, alcohol, or benzodiazepines suddenly can be dangerous; talk to a medical professional first (see Detox and withdrawal management).
The medications
| Condition | Medication | How it is given in the U.S. | Where you can get it |
|---|---|---|---|
| Opioid use disorder | Methadone | Daily dose; take-home doses allowed under federal rules when clinically appropriate | Only at a certified, licensed opioid treatment program (OTP) when used for opioid use disorder |
| Opioid use disorder | Buprenorphine (with or without naloxone) | Tablet or film; extended-release injection; implant | Any practitioner with a DEA registration that includes Schedule III, where state law allows: primary care, outpatient programs, OTPs, and others |
| Opioid use disorder and alcohol use disorder | Naltrexone | Daily tablet or monthly extended-release injection | Any licensed prescriber; it is not a controlled substance |
| Alcohol use disorder | Acamprosate, disulfiram | Tablets | Any licensed prescriber |
Sources for this table: SAMHSA's 42 CFR Part 8 rule and waiver-elimination guidance, and the medication forms SAMHSA's FindTreatment.gov data tracks. Your prescriber will explain how each one works, side effects, and timing. For example, naltrexone is usually started only after opioids have cleared your system, so ask about timing for any medication.
Where to get MAT in New Jersey
- Opioid treatment programs (OTPs). OTPs are the only places that can dispense methadone for opioid use disorder. They may also dispense or prescribe buprenorphine or naltrexone. The State's NJSAMS directory says six New Jersey OTPs currently offer expanded hours, with more hours, telehealth, and fewer administrative barriers, in Atlantic, Gloucester, Hudson, Mercer, Ocean, and Union counties.
- Doctors' offices and clinics. Since December 29, 2022, federal law no longer requires a special "X-waiver" to prescribe buprenorphine for opioid use disorder. Any practitioner whose DEA registration includes Schedule III authority may prescribe it if state law allows, with no federal patient limit. NJ FamilyCare calls care in this setting Office-Based Addiction Treatment (OBAT); the State says OBAT for MAT was covered by NJ FamilyCare managed care plans even before 2025.
- Outpatient, IOP, and partial care programs. Many New Jersey programs start medication, continue medication you already take, or accept patients who get medication elsewhere. Those are different, so ask (see the questions below).
- Residential programs. In 2019 the State said it would require residential treatment facilities that receive Medicaid payment to provide access to MAT. Ask any residential program how it handles medication you already take.
- Telehealth. Under the 2024 federal OTP rule, an OTP may start buprenorphine after an audio-only or video evaluation, and may start methadone after a video evaluation, when a program physician or authorized practitioner decides that evaluation is adequate. Telehealth prescribing outside OTPs follows separate federal DEA rules, which have changed several times; ask the prescriber what currently applies.
How New Jersey regulates opioid treatment programs
- One license chapter since April 6, 2026. The NJ Department of Health (DOH) licenses OTPs under N.J.A.C. 8:43K, the outpatient licensing chapter that replaced N.J.A.C. 10:161B, including New Jersey's older State-specific OTP rules. The OTP section, N.J.A.C. 8:43K-8.1, requires an OTP to be certified under federal standards, including 42 CFR Part 8.
- Aligned with federal rules. In the adoption notice, the Department described the new rules as meant to meet, but not exceed, applicable federal standards.
- Methadone tapering limits. If a person is withdrawing from methadone, N.J.A.C. 8:43K-8.1 requires the OTP's written policies to limit how quickly the dose drops: for a client starting at 100 mg a day, by no more than 10 mg every two days; for a client above 100 mg a day, by no more than 20 percent of the starting dose every two days until the dose is 100 mg or less.
- Naloxone for patients. The adopted rule requires licensed outpatient facilities to make sure all patients with a history of opioid use receive a take-home supply, prescription, and/or information on how to get an opioid overdose antidote. The Department broadened this on adoption from only patients receiving MOUD.
- Policies on request. The Department said facilities must make their patient care policies, including any methadone take-home policies, available to staff, patients, and visitors.
What the 2024 federal OTP rule changed
New Jersey's rule points to 42 CFR Part 8, which SAMHSA revised effective April 2, 2024. According to SAMHSA's summary of the changes, the federal rule:
- Allows take-home doses of methadone from the first week of treatment under certain conditions, based on the practitioner's clinical judgment, with diversion safeguards.
- Removes the requirement of a one-year history of opioid addiction before admission, and the requirement that people under 18 have two documented unsuccessful treatment attempts.
- Says access to medication is no longer contingent on receiving counseling.
- Allows telehealth screening to start buprenorphine (audio-only or video) and methadone (video), as described above.
- Lets nurse practitioners and physician assistants order medication for dispensing at an OTP where state law allows.
- Expands interim treatment from 120 to 180 days, with State approval still required.
NJ FamilyCare (Medicaid) and MAT
- No prior approval for MAT. NJ Medicaid plans stopped requiring prior authorization for medication-assisted treatment of opioid addiction on April 1, 2019. The State's 2026 managed care readiness materials say the State's contract with the health plans explicitly prohibits prior authorization for the delivery of MAT, and that this "is dictated by state law, beyond the MCO contract."
- Opioid treatment programs move into managed care on January 1, 2027. In Phase 2 of the State's behavioral health integration, OTP services move into NJ FamilyCare managed care for most members. The State's materials say MAT services, including MAT delivered by OTPs, remain exempt from prior authorization, including for out-of-network providers. Other services an OTP provides, such as intensive outpatient, still need approval.
- Out-of-network note. The same materials say that for providers outside a plan's network, a request may still be needed for documentation and is reviewed as an "administrative-only" authorization. If anyone tells you MAT needs approval, ask the plan to confirm.
- Plans and member services. See our NJ FamilyCare guide for plan names, member lines, and what to do if something is denied.
Private insurance and MAT
New Jersey's P.L. 2017, c. 28 applies to fully insured New Jersey plans (and the State Health Benefits Plan and School Employees' Health Benefits Plan). The NJ Department of Banking and Insurance says it does not apply to self-funded employer plans, Medicare, Medicaid, TRICARE, or out-of-state plans. For plans it covers, the law says:
- Benefits for outpatient prescription drugs to treat substance use disorder (and, in some sections of the law, "medication-assisted treatments") must be provided when your physician, psychologist, or psychiatrist determines they are medically necessary, without prior authorization or other prospective utilization management.
- The broader c. 28 protections for in-network treatment (no prior authorization for the first 180 days of a plan year, with limits on review) also apply to the counseling and program side of treatment. See Does insurance cover rehab in New Jersey?.
Ask your plan: Is the medication on the formulary? What is my copay? Is my plan fully insured or self-funded (New Jersey ID cards must say which)? Is the OTP or prescriber in network? If a medication or service is denied, see Appeals and denials.
No insurance? ReachNJ and the IME can help you find State-funded options, and some programs offer sliding fees. See No insurance? Help paying for treatment.
Naloxone in New Jersey
Naloxone reverses an opioid overdose. Anyone can carry it.
- Free and anonymous at participating pharmacies (Naloxone365). Anyone 14 or older can ask a pharmacist at a participating pharmacy for naloxone at no cost, with no prescription, no name, and no reason needed. The State says you receive one two-dose, 4 mg nasal spray kit per visit. Find participating pharmacies at the State's StopOverdoses page.
- Standing order. The State notes that the NJ Department of Health issued a naloxone standing order in 2018.
- Over the counter. The FDA approved Narcan 4 mg nasal spray for over-the-counter sale on March 29, 2023.
- From your treatment program. As noted above, New Jersey's outpatient licensing rule requires programs to make sure patients with a history of opioid use get naloxone, a prescription for it, or information on how to get it.
- Free training. The State lists free community naloxone trainings in all three regions of New Jersey.
How to find MAT in New Jersey
- Use a state or federal directory. The State's NJSAMS Addiction Services Treatment Directory includes OTPs and expanded-hours OTPs. SAMHSA's FindTreatment.gov lets you filter for buprenorphine, methadone, and naltrexone. SAMHSA's Opioid Treatment Program Directory lists federally certified OTPs. (SAMHSA removed its search for individual buprenorphine prescribers from FindTreatment.gov in 2026; facilities are still listed.)
- Look at your county. The table below shows how many of the organizations in each of our county guides report each medication service to SAMHSA. Each county page lists them alphabetically with their own phone numbers.
- Ask your primary care provider whether they prescribe buprenorphine or naltrexone, or can refer you.
- Call the State if you are unsure. ReachNJ (1-844-732-2465) and the IME Addictions Access Center (1-844-276-2777).
| County guide | Organizations in the SAMHSA data | Report any medication for addiction | Prescribe buprenorphine | Prescribe naltrexone | Methadone OTP | Accept patients prescribed elsewhere |
|---|---|---|---|---|---|---|
| Bergen County | 19 | 14 | 11 | 12 | 0 | 12 |
| Essex County | 25 | 18 | 14 | 12 | 3 | 20 |
| Hudson County | 13 | 11 | 6 | 7 | 4 | 9 |
| Middlesex County | 22 | 19 | 15 | 16 | 3 | 19 |
| Monmouth County | 23 | 17 | 16 | 13 | 3 | 17 |
| Ocean County | 18 | 17 | 14 | 11 | 4 | 12 |
| Passaic County | 13 | 12 | 7 | 7 | 2 | 8 |
| Union County | 15 | 12 | 8 | 7 | 3 | 7 |
| Camden County | 27 | 25 | 20 | 19 | 4 | 21 |
| Morris County | 18 | 14 | 8 | 9 | 1 | 14 |
| Ten counties combined | 193 | 159 | 119 | 113 | 27 | 139 |
Counts are organizations (not sites) in SAMHSA's FindTreatment.gov substance use facility data as retrieved November 17, 2026, across the ten county guides written so far, after the holds described in our Listing Policy. "Any medication for addiction" means the organization reports using or prescribing buprenorphine, methadone, or naltrexone, or prescribing medication for alcohol use disorder. "Prescribe buprenorphine" and "Prescribe naltrexone" mean the organization reports prescribing it for opioid use disorder. "Methadone OTP" means the organization reports methadone maintenance. "Accept patients prescribed elsewhere" means it reports accepting people whose medication comes from another prescriber. Organizations can report more than one service, so columns do not add to the total. Facilities report these services themselves, and the counts can be out of date or differ from a facility's own description; call to confirm. Other New Jersey counties will be added as their guides are written.
Questions to ask a program or prescriber
- Do you start medication yourselves, continue medication I already take, or only accept patients prescribed elsewhere?
- Which medications do you offer: methadone, buprenorphine (and which forms), naltrexone (tablet or injection), acamprosate, disulfiram?
- How soon can I start? Do you offer same-day or next-day starts, or telehealth?
- For an OTP: what are your dosing hours, and what is your take-home policy? Do you offer guest dosing if I travel?
- Is counseling offered, and is it required to keep receiving medication?
- Are you in network with my plan? What will I pay for visits and for the medication?
- Do you provide naloxone?
- What happens if I want to reduce or stop the medication later?
More questions are in How to choose a treatment facility, and you can check a program's license with How to check that a program is licensed. New Jersey law bars treatment providers from misstating their network status, location, affiliations, or services, and makes it a crime to pay or offer anything of value for patient referrals (P.L. 2025, c. 121 and c. 122).
Need help sorting through options?
If a partner facility is not a fit for you, we will say so and point you to other options, including ReachNJ and the programs listed in our county guides. You can always call any program directly.
Related pages
- Back to Levels of addiction treatment care in New Jersey
- Back to Finding addiction treatment in New Jersey
- Starting Suboxone or methadone in New Jersey: finding a program, paying, first visit
- Detox · Outpatient · Intensive outpatient · Partial hospitalization · Residential · Co-occurring mental health and substance use care
- NJ FamilyCare and addiction treatment · Does insurance cover rehab in New Jersey? · No insurance? · Appeals and denials
- County guides with medication counts: Bergen · Essex · Hudson · Middlesex · Monmouth · Ocean · Passaic · Union
Frequently asked questions
What is MAT?
MAT, or medications for addiction treatment, means FDA-approved medicines for opioid or alcohol use disorder, usually combined with counseling. For opioid use disorder they are methadone, buprenorphine, and naltrexone; for alcohol use disorder they are naltrexone, acamprosate, and disulfiram.
Where can I get methadone in New Jersey?
Only at a certified opioid treatment program (OTP), licensed by the New Jersey Department of Health under N.J.A.C. 8:43K. Search the State's NJSAMS directory or SAMHSA's Opioid Treatment Program Directory, or call ReachNJ at 1-844-732-2465.
Do I need a special doctor to get buprenorphine?
No. Since December 29, 2022, federal law no longer requires an X-waiver. Any practitioner whose DEA registration includes Schedule III authority may prescribe buprenorphine for opioid use disorder where state law allows, including many primary care providers.
Does NJ FamilyCare require prior approval for MAT?
No. NJ Medicaid removed prior authorization for opioid addiction medication in 2019, and the State's contracts with NJ FamilyCare plans prohibit prior authorization for delivering MAT. When OTPs move into managed care on January 1, 2027, MAT through OTPs stays exempt from prior authorization, though other OTP services such as IOP still need approval.
Does private insurance in New Jersey cover addiction medications without prior authorization?
For fully insured New Jersey plans, P.L. 2017, c. 28 says medically necessary outpatient prescription drugs to treat substance use disorder must be covered without prior authorization or other prospective utilization management. Self-funded employer plans, Medicare, and TRICARE follow other rules, so check which type of plan you have.
Can I get take-home methadone?
Possibly. The 2024 federal OTP rule allows take-home doses from the first week of treatment under certain conditions, based on the practitioner's clinical judgment. New Jersey's licensing rule requires OTPs to follow those federal standards. Ask the OTP for its take-home policy.
Where can I get free naloxone in New Jersey?
Anyone 14 or older can get a free two-dose naloxone nasal spray kit, anonymously and without a prescription, at participating pharmacies through the State's Naloxone365 program. Find pharmacies on the State's StopOverdoses page. Narcan nasal spray is also sold over the counter.
Can I keep taking my medication if I go to residential treatment or IOP?
Ask the program before you enroll. Programs differ: some start medication, some continue it, and some only accept people prescribed elsewhere. In 2019 the State said residential facilities receiving Medicaid would have to provide access to MAT.
Is this a government website?
No. Garden State Recovery Guide is operated by Treatment Outreach, a private company. The NJ Department of Health, DMHAS, ReachNJ, and 988 are public services we link to but do not run.
Sources
- NJ Department of Health, Notice of Adoption, N.J.A.C. 8:43K (outpatient licensing; repeal of N.J.A.C. 10:161B; OTP rule at 8:43K-8.1 including methadone withdrawal policy limits; responses to comments 1, 99, and 124 and the change to 8:43K-5.1(b)7 on opioid antidotes), adopted Jan. 15, 2026, effective April 6, 2026: https://nj.gov/health/legal/documents/adoption/8_43K NOA.pdf
- SAMHSA, 42 CFR Part 8 Final Rule: Table of Changes: https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8/changes
- Federal Register, Medications for the Treatment of Opioid Use Disorder (final rule, Feb. 2, 2024; effective April 2, 2024; telehealth initiation; naltrexone not a controlled medication): https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder
- SAMHSA, Waiver Elimination (MAT Act) (Consolidated Appropriations Act, 2023, sec. 1262; Schedule III DEA registration; 2026 removal of individual prescriber search): https://www.samhsa.gov/substance-use/treatment/resources/mat-act
- DEA Diversion Control Division, Dear Registrant letter on elimination of the DATA-Waiver (no patient limits): https://www.deadiversion.usdoj.gov/pubs/docs/dear-registrant-AM-01122023.html
- NJ Department of Human Services, "New Jersey Medicaid Removes Prior Authorization Requirements for Opioid Addiction Treatment Medication" (April 1, 2019): https://www.nj.gov/humanservices/news/pressreleases/2019/approved/20190401.shtml
- NJ DMHAS, Behavioral Health Managed Care Provider Readiness Packet (OBAT already in managed care; MAT prior authorization prohibition; Phase 2 OTP changes; out-of-network administrative-only authorization): https://www.nj.gov/humanservices/dmhas/documents/pdf/BH-Integration-Provider-Readiness-Packet.pdf
- P.L. 2017, c. 28 (C.17:48-6nn et al.), substance use disorder benefits, including the prescription drug and medication-assisted treatment subsections: https://pub.njleg.state.nj.us/Bills/2016/PL17/28_.PDF
- NJ Department of Banking and Insurance, Bulletin 17-05 (Chapter 28 applicability): https://www.nj.gov/dobi/bulletins/blt17_05.pdf
- NJ DMHAS, NJSAMS Addiction Services Treatment Directory (OTP description; six expanded-hours OTPs): https://njsams.rutgers.edu/treatmentdirectory/
- SAMHSA, Opioid Treatment Program Directory: https://dpt2.samhsa.gov/treatment/directory.aspx
- SAMHSA FindTreatment.gov, county-level medication counts from the pulls behind each county guide, retrieved 2026-11-17: https://findtreatment.gov/
- NJ Department of Human Services, StopOverdoses / Naloxone365 (free, anonymous naloxone at participating pharmacies, age 14+; DOH standing order; community trainings): https://www.nj.gov/humanservices/stopoverdoses/
- NJ Department of Human Services, Naloxone365 one-pager (two-dose 4 mg kit; 2018 standing order): https://www.nj.gov/humanservices/resources/Naloxone365_OnePager_v1.pdf
- U.S. FDA, "FDA Approves First Over-the-Counter Naloxone Nasal Spray" (March 29, 2023): https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray
- ReachNJ: https://nj.gov/humanservices/reachnj/about/overview/
- IME Addictions Access Center (NJ 2-1-1): https://nj211.org/initiative/addiction-referral-and-support-service
- P.L. 2025, c. 121 and c. 122: https://pub.njleg.state.nj.us/Bills/2024/AL25/121_.PDF , https://pub.njleg.state.nj.us/Bills/2024/AL25/122_.PDF
- N.J.S.A. 2C:35-30 (overdose prevention): https://lis.njleg.state.nj.us/nxt/gateway.dll/statutes/1/2785/3300